Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $12.00 price target on SAB Biotherapeutics (NASDAQ: SABS).The analyst commented: "SAB's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE